Plaintiffs Reach Settlement with the Mylan Defendants in EpiPen Class Action
March 1, 2022 – Plaintiffs in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, have reached a $264 million settlement with the Mylan Defendants to resolve class claims that Mylan, together with the Pfizer Defendants, engaged …
Plaintiffs Reach Settlement with the Mylan Defendants in EpiPen Class Action Read More »